Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
| Autor: | Crysler, Oxana V., Yarchoan, Mark, Furuse, Junji, Galle, Peter R., Sukeepaisarnjaroen, Wattana, Thinh, Nguyen Tien, Masi, Gianluca, Lim, Ho Yeong, Varela, Maria, Gupta, Charu, Makowsky, Mallory, Negro, Alejandra, Abou-Alfa, Ghassan K. |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p551-551, 1p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|